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Abstract 
Background: Multiple myeloma (MM) is a clonal B cell malignancy characterized by proliferation of malignant 
plasma cells in the bone marrow. Despite high‑dose melphalan therapy with autologous stem cell transplantation 
(ASCT) and the introduction of immunomodulatory drugs like bortezomib or lenalidomide, that have been associated 
with improved survival, MM is still incurable and new treatment options are needed. In B cell malignancies such as 
chronic lymphocytic leukaemia (CLL) or diffuse large B cell lymphoma (DLBCL), Syk (spleen tyrosine kinase) inhibitors 
have shown promising in vitro and first clinical results. In our study, we analyzed the potential of Syk as a target in MM.
Methods: The MM cell lines AMO‑1, U266 and RPMI8226 and primary MM cells were treated with the Syk inhibi‑
tors BAY61‑3606, R406 or Piceatannol and proliferation, migration and apoptosis induction were analyzed. Effects on 
involved intracellular signaling cascades were determined by Western blotting. Furthermore, we analyzed synergistic 
and additive effects of Syk inhibitors in combination with established anti‑myeloma drugs and experimental inhibitors 
(e.g. PI‑3‑Kinase inhibitor NVP‑BEZ235).
Results: Incubation of MM cell lines as well as primary MM cells with Syk inhibitors resulted in a reduced proliferation 
and stromal cell‑derived factor‑1 alpha (SDF‑1 alpha) induced migration that was accompanied by a concentration 
dependent inhibition of the MAP‑Kinase, characterized by reduced phosphorylation of ERK an p38 molecules, and NF‑
kappaB signalling pathways. Furthermore, Syk inhibition induced apoptosis in MM cells in a dose‑dependent manner, 
characterized by reduced expression of pro‑caspase 3, increased PARP‑1 cleavage and enhanced release of cytochrome 
c. In addition combined treatment of MM cells with Syk inhibitors and NVP‑BEZ235 (dual PI3‑kinase/mTOR inhibitor) or 
MAPK inhibitors (PD98059, SP600125, U0126, SB203580) resulted in increased apoptotic activity of the drugs.
Conclusions: Our results show that Syk inhibition might represent a promising new treatment option in MM with 
an increased efficacy when combined with MAP kinase inhibitors. Furthermore, our study strongly underlines the 
potency of Syk inhibitors as a potential therapeutic treatment option for MM patients.
Keywords: Spleen tyrosine kinase (Syk), Syk inhibitors, Multiple myeloma, Plasmacell malignancy, Tyrosine kinase, 
Apoptosis, Signal transduction Bay61‑3606, Piceatannol, R406
© 2015 Koerber et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  Peter.Brossart@ukb.uni‑bonn.de 
†Ruth‑Miriam Koerber and Stefanie Andrea Erika Held contributed equally 
to this study
Medical Clinic III, Department of Hematology and Oncology, University 
Hospital Bonn, Sigmund‑Freud‑Str. 25, 53127 Bonn, Germany
Background
Multiple myeloma (MM) is a B cell clonal malignancy char-
acterized by proliferation and accumulation of malignant 
plasma cells within the bone marrow (BM) [1]. Several 
recently introduced therapies such as bortezomib, thalido-
mide or lenalidomide as well as high dose chemotherapy 
and autologous stem cell transplantation (ASCT) have 
improved the prognosis and overall survival of patients 
with MM. However, MM is still an incurable disease [2, 3].
Drug resistance represents one of the major difficulties 
to overcome in patients with malignant disease which 
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often results in failure to eliminate minimal residual 
tumor cells [4, 5]. Studies performed in an attempt to 
determine the factors mediating drug resistance and 
survival of malignant cells led to the characterization 
of novel pathways and identification of potential targets 
for anticancer therapies [6, 7]. In malignant B cells and 
plasma cells, the involvement of signalling pathways 
via Janus kinases 1/2 (JAK1/2) and the signal transduc-
ers and activators of transcriptions (STAT) molecules as 
well as the events mediated by the phosphatidylinositol-3 
kinases (PI3-K) and mitogen activated kinases (MAPK) 
were found to be critical for cell growth, differentiation 
and survival [8–10].
In addition, emerging evidence suggests that spleen 
tyrosine kinase (Syk), an intracellular tyrosine kinase, 
plays a central role upon activation of cells by B or T cell 
receptors (BCR or TCR) as well as by cytokines or adhe-
sion molecules [11–13]. Syk activation is mediated when 
sarcoma kinases (Src kinases) phosphorylate conserved 
sequences within receptors containing immune tyrosine 
activation motifs (ITAMs) [14, 15]. Once activated, Syk 
propagates the phosphorylation of further downstream 
molecules including the PI3-K and MAP-kinase path-
ways [16, 17].
Syk and the zeta-chain-associated protein kinase 70 
(ZAP-70) are the only members of the Syk family kinases. 
Syk was first identified by isolation of tyrosine kinase 
activity found in the thymus and spleen leading to the 
cloning of the 72 kDa protein [18, 19]. Mice with geneti-
cally disrupted Syk are deficient in B cell maturation and 
expansion and die prenatally due to severe bleedings. 
This indicates that Syk might play a role in angiogen-
esis and maintaining of vascular integrity [20, 21]. Sub-
sequently, Syk has been found to be involved and play a 
broad role in hematopoietic cell signalling such as FCeRI 
receptor in mast cells, FCgRIIA in macrophages and 
platelets as well as the antigen receptors of B and T cells 
[22, 23]. In addition, it was demonstrated that Syk is also 
expressed in fibroblasts, hepatocytes, neuronal cells and 
vascular endothelium [24]. Syk was shown to function 
as an oncogene and to be a negative regulator of tumori-
genesis in some malignant diseases such as breast cancer, 
B and T cell lymphoma and myelodysplastic syndromes 
[25, 26].
Recently, several reports on preclinical studies dem-
onstrated that Syk inhibition might represent a rational 
therapeutic target in B cell malignancies such as chronic 
lymphocytic leukaemia (CLL), diffuse large B-non-Hodg-
kin lymphoma (DLBCL), follicular and mantle cell lym-
phoma by interfering with the signalling promoted by 
the activation via the BCR, cytokines and stromal factors 
[27–29]. In DLBCL and CLL, first clinical experiences 
with the clinically available Syk inhibitor R406 provided 
encouraging and promising results in heavily pre-treated 
patients [30–32].
In our study we analyzed the effects of the three cur-
rently available Syk inhibitors, Piceatannol, Bay-61-3606 
and R406 on the viability and functional properties of 
myeloma cells in order to provide a mechanistic under-
standing and a rationale for a possible use of these com-
pounds as therapeutic option.
Results
Syk inhibitors reduce the proliferation and migration 
of MM cells
Syk was shown to play an important role in the signal 
transduction via the BCR, cytokine receptors, integrins 
and Fc receptors on normal and malignant B cells. These 
receptors promote survival and are associated with the 
induction of proliferation, differentiation and migration. 
Using Immunoprecipitation, we found that phosphoryl-
ated Syk is expressed in the utilized multiple myeloma 
cell lines AMO-1, U266 and RPMI8226. Furthermore, 
Syk expression was also detected in primary MM cells 
of patients with plasma cell leukemia (PCL). In addition, 
we found that Syk can be downregulated when these 
myeloma cells were incubated with the inhibitors of Syk 
phosphorylation, i.e. Bay 61-3606 or Piceatannol and 
R406 (Fig. 1a, b).
Incubation of MM cell lines with Piceatannol, R406 or 
Bay 61-3606 led to a concentration dependent decrease 
of proliferation, as analyzed by 3H-thymidine incorpo-
ration, and to a reduced stromal cell-derived factor-1 α 
(SDF-1α) induced migration of cells in transwell experi-
ments as depicted in Fig. 2a and b for the AMO-1 cells. 
Similar results were obtained with other MM cell lines 
(U266 and RPMI8226).
Additionally, we performed MTT (tetrazolium salt 
3-4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium 
bromide) cytoxicity assays to ensure that the effects on 
migration and proliferation induced by Syk inhibitors 
are not due to cytotoxicity as a mechanism of action. 
The MTT assays showed no decline in cell viability when 
incubated with Syk inhibitors. This was proved in three 
cell lines at three different concentrations. Based on these 
results, the effects of the various Syk inhibitors on migra-
tion and proliferation are not due to cytotoxic effects (see 
Additional file 1).
In line with these results, we found that treatment of 
cells with the compounds resulted in a reduced activation 
of the downstream signalling events characterized by 
reduced phosphorylation of extracellular signal-regulated 
kinases 1/2 (ERK1/2) and p38 mitogen-activated protein 
kinases (Fig.  3a, b) and nuclear localized expression of 
transcription factors of the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) family RelB 
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and RelA (Fig. 3c). Representatively, the results are shown 
for AMO-1 cell line. However, all used MM cell lines 
(U266 and RPMI-8226) showed similar results in our 
experiments. The utilized concentrations of Syk inhibi-
tors were adjusted to reported working concentrations in 
the literature.
Inhibition of Syk induces apoptosis in MM cells
In order to analyze the effect of Syk inhibitors on the via-
bility of established MM cell lines, Piceatannol, R406 or 
Bay61-3606 were added to the cell culture medium and 
flow cytometric propidium iodide (PI) analysis of DNA 
fragmentation was performed as described previously 
[33]. Incubation of cells with the compounds resulted in 
a concentration dependent cell death induction that was 
inhibited by the addition of the pan-caspase inhibitor 
zVAD-FMK. This indicates that caspase activity was indis-
pensable for the observed apoptotic effects (Fig. 4a, b).
Likewise, we wanted to determine the efficacy of the 
compounds to induce apoptosis in purified MM cells. As 
shown in Fig.  4c, incubation of primary MM cells from 
patients with plasma cell leukemia with R406, Piceatan-
nol or Bay61-3606 significantly reduced cell viability.
Caspase-3 assays and Western Blot analysis revealed 
that the induction of apoptotic cell death was accompa-
nied by caspase-3 activation and poly[ADP ribose]poly-
merase 1 (PARP-1) cleavage (Fig.  5a, b). In addition, an 
increased release of cytochrome c upon incubation with 
the compounds indicated that the apoptosis induction 
in tested MM cells was mediated via the mitochondrial 
signalling pathway (Fig. 5c). In contrast to previous find-
ings in CLL cells, we could not detect any regulation of 
the expression of myeloid leukaemia cell differentiation 
protein MCL-1, the x-linked inhibitor of apoptosis pro-
tein xIAP or survivin (also known as BIRC5 or API4) by 
the used compounds (Fig. 5c).
IL-6 is a major growth and drug-resistance factor for 
MM cells that activates a cascade of signalling pathways 
mediating proliferation and anti-apoptotic effects. We 
therefore analyzed whether IL-6 might interfere with and 
abrogate the apoptotic effects induced by Syk inhibitors. 
Preincubation of MM cells with IL-6 had no effect on 
Piceatannol triggered apoptosis in MM cell lines (Fig. 6). 
Similarly, preincubation of MM cell lines with TLR 
ligands (TLR 2, 3, 4, 7/8) had no effect on the action of 
Syk inhibition (data not shown).
Because bone marrow (BM) microenvironment pro-
motes MM survival and drug resistance, we next deter-
mined the apoptosis induction in MM cells in this 
context. The majority of MM patients expresses the 
chemokine receptor CXCR4 on neoplastic MM cells 
which is crucial for myeloma cell migration and hom-
ing to the BM microenvironment. Additionally, it sup-
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Fig. 1 a, b Expression of Syk and phosphorylated Syk in different cell lines and patient samples. a Syk was immunoprecipitated from MM cell lines 
and primary MM cells. Immunoprecipitates were subjected to Western blotting using specific antibodies. Primary myeloma cells were obtained 
from peripheral blood of myeloma patients with plasma cell leukemia (PCL, purity >90%). Displayed is a representative immunoblot of Syk and pSyk 
in the absence of Syk inhibitors which shows Syk expression in the utilized MM cell lines and PCL‑cells. b and c Addition of Syk inhibitors (Picea‑
tannol, R406 and Bay61‑3606) reduce the expression of pSyk in MM cell lines and PCL cells. Ponceau S staining was performed to confirm equal 
amounts of protein.
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resistance. For contacts of cell–cell and cell to extracel-
lular matrix, a group of cellular adhesion molecules such 
as CD11a or CD49d are essential, likewise their ligands, 
i.e. CD102 (ICAM 2). Surface antigens were examined 
by flow cytometric analysis. Despite reduced migration 
of cells when treated with Syk inhibitors, we could not 
detect any effect on the expression of CXCR4, CD49d or 
CD102 on the cell surface of MM cells (data not shown).
Combined treatment of MM cells with Syk 
inhibitors
In the next set of experiments we analyzed possible 
additive effects of drugs currently used in the treat-
ment of MM with Syk inhibitors. We found no additive 
effects when Syk inhibitors were used with bortezomib 
(Fig.  7a). In addition, no additive effects were detected 






























































































































































































































































































Fig. 2 a, b Syk inhibitors reduce proliferation and migration in a dose‑dependent manner. a MM cell lines were incubated with Syk inhibitors 
(Piceatannol or Bay61‑3606) for 24 h and the proliferative response was analyzed by 3H‑thymidine uptake. Syk inhibition resulted in a decrease of 
cell proliferation. b Migration of MM cells towards SDF‑1α were performed with or without Syk inhibitors (Piceatannol, Bay61‑3606 and R406) using 
transwell chemotaxis assays. The percentage of migrated cells was determined after 3 h by flow cytometry. Syk inhibitors diminished the migration 
towards SDF‑1α stimulated cells. The shown results are representative for all tested MM cell lines. Results are expressed as the mean of three panels 
per pattern. Results are shown from one experiment representative of at least three. DMSO or Ampuwa was used as control. The significance is 
related to DMSO/Ampuwa. +P < 1.000, *P < 0.1, **P < 0.01, ***P < 0.001.
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lenalidomide, TRAIL (tumor necrosis factor related 
apoptosis inducing ligand) or dexamethasone (data not 
shown).
NVP-BEZ235, an orally available dual PI3 kinase/mTor 
inhibitor, was recently shown to suppress survival and 
growth of MM cells in preclinical studies. We found that 
combined treatment of MM cells with Piceatannol and 
NVP-BEZ235 significantly increased the cytotoxic effect 
as compared to each drug alone (Fig. 7a). This was pre-
dominantly observed in AMO-1 cells. Significant results 
could be observed in both cell lines when correlated to 
Piceatannol, in U266 cells significances correlated to 
NVP-BEZ235 were not significant, but in AMO-1 they 
were significantly higher (see Additional file 1).
As mentioned above, MAP-Kinases play a critical role 
in differentiation, cell growth and survival in MM. Com-
bination of Syk inhibitors with MAP-Kinase inhibitors 
such as U0126 (a potent, selective inhibitor of MAP2K), 
PD98059 (an inhibitor of MAP2K/MEK), SP600125 (a 
selective inhibitor of JNK) and SB203580 (a selective 
inhibitor of p38 MAPK) resulted in synergistic cytotoxic 
effects in combination with U0126 (Fig. 7b) and PD98059 
(Fig. 7d). Additive effects were observed when combined 
with SP600125 (a selective inhibitor of JNK, Fig.  7c) or 
SB203580 (Fig. 7e).
Discussion
In our study we demonstrate that a proportion of MM 
cells express Syk and pSyk and Syk inhibitors R406, 
Piceatannol and Bay61-3606 effectively block prolifera-
tion, migration and survival of MM cells. This indicates 
that Syk inhibition might represent a potential new ther-
apeutic option in the treatment of MM. However, the 
compounds we used in our experiments are not entirely 
specific for Syk and do display some lower activity against 
JAK, Lck, Lyn, STAT3 and STAT 5 as well as against 
some potential additional, yet to be determined, tyrosine 
kinases [34, 36, 37].
R406 and BAY61-3606 have previously been reported 
to inhibit proliferation and to induce apoptosis in non-
Hodgkin lymphoma (B-NHL) and CLL cells [27, 38]. 
R406 is currently used in clinical trials and has demon-
strated promising activity in patients with B-NHL, ITP 
and rheumatoid arthritis [39, 40]. The so far reported side 
effects of the compound are generally mild and consist 
primarily of gastrointestinal side effects and neutropenia, 
which was dose related and rapidly reversible upon dose 
reduction or discontinuation of treatment [41]. Interest-
ingly, in mice treated with R406, additional immunomod-
ulatory effects including lymphopenia, reduced thymus 
and spleen weight and decreased cellularity of the BM 
were observed, which resolved within 2 weeks after stop-
ping the drug application [42].
MM cells express the chemokine receptor CXCR4 
and its ligand SDF-1α controls their α4β1-mediated 
adhesion to the vascular adhesion molecule 1 (VCAM-
1), fibronectin and endothelial cells as well as their 
transendothelial migration and homing in the BM [43, 
44]. MM cells are highly dependent on BM microen-
vironment, where signals provided by cytokines and 
adhesion molecules promote the survival, proliferation 
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Fig. 3 a–c Syk inhibition reduces phosphorylation of p38 and ERK1/2 in MM cell lines. a, b MM cell lines were treated with Piceatannol at con‑
centrations of 10 and 25 µM. Phosphorylation status of down stream signaling mediators p38‑Kinase and ERK1/2‑Kinase (MAPK p42 and p44) was 
evaluated by Western blotting using antiphospho‑p38 and antiphospho‑ERK 1/2 antibodies. GAPDH was used to confirm equal amounts of protein. 
Results are representative of at least three independent experiments. c Nuclear translocation of NF‑κB family members was determined by Western 
Blot analysis of nuclear extracts upon incubation with Syk inhibitors (c). Piceatannol was applied at 10 and 25 µM. DMSO was used as control. 
Proteins detected are indicated by an arrow on the right. Ponceau S staining was performed to confirm equal amounts of protein. Results are repre‑
sentative of at least three independent experiments.
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found that treatment of MM cells with Syk inhibitors 
blocked the SDF-1α mediated migration of MM cells 
and abrogated the survival signals provided by IL-6, 
TLR ligands or BM stroma. These blocking effects 
were accompanied by the inhibition of downstream 






















































































































































































































































































































































































































































Fig. 4 a–c Inhibition of Syk induces apoptosis in MM cell lines. a–c Viability of MM cells was defined by the amount of nuclear fragmentation and 
compared to the respective DMSO control. MM cell lines [AMO‑1 (a), U226 (b) and primary MM cells from patients with plasma cell leukemia (purity 
>90%) (c)] were treated with various concentrations of Syk inhibitors (Piceatannol, R406 and Bay61‑3606) as indicated. After 24 h of incubation with 
Syk inhibitors, propidium iodide‑staining was performed. Nuclear fragmentation was determined by flow cytometry. zVAD‑FMK was added as con‑
firmation for caspase activation (white bar graphs). c Primary MM cells were isolated from peripheral blood from patients with plasma cell leukemia 
(purity >90%) and analyzed as described above. Results are expressed as the mean of three panels per pattern. Results are from one experiment 
representative of at least three. The significance is related to DMSO as control. +P<1.000, *P < 0.1, **P < 0.01, ***P < 0.001.
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Fig. 5 a, b Caspase‑3 activity is increased significantly upon treatment with Syk inhibitors. a Caspase‑3 activity was determined from whole cell 
lysates by the cleavage of the fluorogenic caspase substrate N‑acetyl‑Asp‑Glu‑Val‑Asp‑aminomethylcoumarin (DEVD‑AMC). The release of ami‑
nomethylcoumarin was determined by fluorometry using an excitation length of 360 nm and an emission wave‑length of 460 nm. Syk‑Inhibitors 
induce a significant concentration‑dependent increase of caspase‑3 activity. Results are expressed as the mean of three panels per pattern. Results 
are from one experiment representative of three. DMSO was used as control. The significance is related to DMSO. +P<1.000, *P < 0.1, **P < 0.01, 
***P < 0.001. b Western Blot analyses of AMO‑1 whole cell lysates treated with Piceatannol was utilized to analyze the expression of pro‑caspase 3 
and PARP‑1 cleavage. After 24 h of incubation with Syk inhibitors, whole cell lysates were prepared and Western Blot analysis was performed. DMSO 
was used as a control. GAPDH was used to confirm equal amounts of protein. Results are representative of at least three independent experiments. 
Proteins detected are indicated by an arrow on the right. c Expression of xIAP, Mcl‑1, cytochrome c and Survivin upon treatment with Syk inhibitors. 
Protein extracts were analyzed for the expression of proteins participating in apoptosis such as xIAP, Mcl‑1, survivin and cytochrome c by immuno‑
blotting. An increase of cytochrome c was observed, implicating that Piceatannol induces apoptosis via the internal, mitochondrial pathway. There 
was no effect of Piceatannol on the anti‑apoptotic proteins survivin, Mcl‑1 and xIAP. Results are representative of various independent experiments. 
Proteins detected are indicated by an arrow on the right.
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p38 phosphorylation and nuclear localized RelB and 
RelA, indicating that MAP-Kinase and NF-κB signal-
ling pathways are involved in the observed inhibitory 
effects.
Syk inhibitors efficiently induced apoptosis in estab-
lished MM cell lines and purified MM cells. This was 
characterized by an enhanced caspase-3 activity and 
PARP-1 cleavage, a known caspase-3 substrate. The 
induction of cell death was inhibited by the addition of 
the pan-caspase inhibitor zVAD-FMK, further confirm-
ing the critical role of caspases in this setting. In addition, 
we found that Syk inhibition resulted in enhanced release 
of cytochrome c indicating that the apoptotic cell death 
was mediated via the internal, mitochondrial pathway.
Our findings are in line with previous findings in CLL 
cells [38] where treatment of CLL cells with BAY61-3606 
caused caspase-3 activation, cleavage of PARP-1 and loss 
of mitochondrial potential. However, in contrast to this 
report we could not detect any regulation of MCL-1 pro-
tein expression in our experiments indicating that the 
effects and mechanisms induced by the utilized com-
pounds may vary depending on the used cell lines and 
models.
The introduction of recently developed agents such 
as the proteasome inhibitor bortezomib or lenalido-
mide has dramatically improved the prognosis and 
overall survival in MM patients [47, 48]. Some of the 
induced effects by these targeted therapies are medi-
ated by interfering with the MAP-Kinase and NF-kB sig-
nalling pathways. Therefore, we hypothesized that Syk 
inhibition might represent a rationale combination part-
ner. While there were no additive effects by bortezomib, 
the combined treatment of MM cells with MAP-Kinase 
inhibitors resulted in an increased cytotoxic effect. In 
addition, we observed that simultaneous exposure to 
NVP-BEZ235 [49], an orally available dual inhibitor of 
PI3 kinase/mTor signalling significantly enhanced the 
efficacy of Syk inhibitors.
Conclusions
Syk inhibitors already showed promising results in B 
cell malignancies such as CLL and DLBCL. Our data 
show successful findings of Syk inhibition in MM. Syk 
inhibition in MM resulted in decreased proliferation 
and migration of MM cells. Additionally, Syk inhibition 
induces apoptosis and is effective in combination with 
established anti myeloma drugs and experimental new 
kinase inhibitors, such as a PI3-Kinase inhibitor. In sum-
mary, our study provides a mechanistic insight and a 
rationale for Syk inhibition as a novel therapeutic option 
for the treatment of MM.
Methods
Cell culture
The cells lines AMO-1, U266, RPMI8226 and MM1-S 
were a kind gift from Helmut Salih from the University 
Hospital Tuebingen. The cells were cultured in RP10 
medium (RPMI 1640 containing GlutaMAX, supple-
mented with 10% heat-inactivated fetal calf serum and 































































































































































Fig. 6 Efficiacy of Syk inhibition on cell viability is not reduced in the presence of Il‑6. To determine the impact of IL‑6 on the apoptotic effects 
of Syk inhibitors, MM cells were preincubated with IL‑6 and nuclear fragmentation of MM cells treated with Syk inhibitors was measured by flow 
cytometry. In comparison with Bay61‑3606 or Piceatannol alone, a combination with IL‑6 did not reduce significantly the number of apoptotic cells. 
Results are expressed as the mean of three panels per pattern. Results are from one experiment representative of three. DMSO was used as control. 
The significance is related to DMSO. +P<1.000, *P < 0.1, **P < 0.01, ***P < 0.001.
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Karlsruhe, Germany) in a humidified atmosphere 
(37°C, 5% CO2). Cells were seeded into 75 cm2 flasks at 
104/10 ml/flask (BD Heidelberg, Deutschland).
After informed consent, blood samples were collected 
from patients with multiple myeloma hospitalized at 
the University Hospital Bonn. PBMCs were isolated by 
Ficoll/Paque (Biochrom, Berlin, Germany) density gradi-
ent centrifugation.
Cells were preincubated with zVAD (Bachem Distri-
bution Services GmbH, Weil am Rhein, Germany) for 
1 h. Piceatannol, applied at concentrations of 10, 25 and 
50  µM (Sigma-Aldrich Chemie GmbH, Munich, Ger-
many), R406, applied at concentrations of 1 and 5  µM, 
and BAY61-3606, applied at concentrations of 1, 2.5 and 
5  µM, (Sigma-Aldrich Chemie GmbH, Munich, Ger-
many) were added for 24  h. After 24  h, cells were pre-
pared for further experiments.
To analyse possible synergistic effects we tested in 
addition thalidomide(MP Biochemicals, Solon, Ohio, 
USA), lenaldomide (Selleck Biochemicals, Houston, TX, 
USA) TRAIL (R&D Systems, Minneapolis, MN, USA), 
NVP-BEZ235 (Novartis Deutschland GmbH, Nürnberg, 
Germany), Bortezomib (Millenium Pharmaceuticals 
Limited, Cambridge, MA, USA) and five MAPK Inhibi-
tors (PD98059, SB203580, SP600125, U0126, SB201290 
all purchased from Tocris Bioscience, MO, USA).
Preparation of whole cell lysates and nuclear extracts
For the generation of whole cell lysates, cells were lysed 
in RIPA buffer containing 1% Igepal CA-630, 0.5% Na-
Deoxycholat, 0.1% SDS, 2 mM EDTA, 2 µg/ml Aprotinin, 
1 mM PMSF. Protein concentration was measured using 
a bicinchoninic acid (BCA) assay (Pierce, Perbio Science, 
Bonn, Germany).
Nuclear extracts were prepared as described. In brief, 
106 cells were incubated in 400  µl Buffer A containing 
10  mM HEPES pH 7.9, 10  mM KCL, 0.1  mM EDTA, 
0.1 mM EGTA, 1 mM DTT and 0.5 mM PMSF. Cellular 
membranes were destroyed by addition of 10% Igepal 
CA-630 and vigorous vortexing. Nuclei were pelleted by 
centrifugation and resuspended in buffer C containing 
20  mM HEPES pH 7.9, 0.4  M sodium chloride, 1  mM 
EDTA, 1  mM EGTA, 1  mM DTT and 0.5  mM PMSF. 
Nuclear proteins were recovered by centrifugation for 
5 min at 20,000g.
PAGE and Western blotting
20  µg of whole cell lysates or nuclear extracts of 
1 ×  106 cells were separated by SDS-PAGE and sub-
sequently transferred onto nitrocellulose membranes 
(Whatman, Dassel, Germany). The blots were probed 
with antibodies against bcl-x, cytochrome c, cas-
pase-3, XIAP (all purchased from BD Biosciences, 
Heidelberg, Germany), ERK 1/2, mcl-1, survivin, Rel-
A, Rel-B (all purchased from Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, USA), p38, pp38 (all purchased 
from Cell Signaling Technology®, MA, USA). GAPDH 
(Santa Cruz Biotechnology, Inc., Santa Cruz, USA) 
was used as a loading control. Signals were detected 
using the ECL detection system (GE Healthcare, 
Munich, Germany).
Immunoprecipitation
To estimate the expression of the protein tyrosine kinase 
syk in our multiple myeloma cell lines we performed 
immunoprecipitation. Cell lysates were assembled as 
explained above (see preparation of whole cell lysates). 
For immunoprecipitation Dynabeads® Protein A or Pro-
tein G from Invitrogen (Life Technologies GmbH, Darm-
stadt, Germany) were used. The primary antibodies (3 µl/
sample) were pooled to 50 µl Dynabeads® Protein A and 
G. To isolate the generated complexes we washed (each 
with 200 µl AB Binding und Wasch Puffer) the solution 
and the suspension was passed by two magnets where the 
magnetic beads were reversibly trapped in the magnetic 
field and formed a compact dense plug.
(see figure on previous page.)
Fig. 7 Combined treatment with NVP‑BEZ235 or MAPK inhibitors increases induction of apoptosis. a Nuclear fragmentation of MM cells treated 
with either/and 500 nM NVP‑BEZ235, 25 µM Piceatannol and 0.5 ng bortezomib. Nuclear fragmentation was determined by the method of Nicoletti 
and analysed by flow cytometry. In comparison to Piceatannol alone, a combination with the common anti‑myeloma agent bortezomib exerts no 
further increase of nuclear fragmentation. The addition of NVP‑BEZ235 (an orally bioavailable dual phosphatidylinositol 3‑kinase/mammalian target 
of rapamycin inhibitor) to Syk inhibitors increased nuclear fragmentation. Statistical analysis showed, that the combination of NVP‑BEZ235 and 
Piceatannol is significantly higher than each drug alone. This works predominantly for AMO‑1 cells. Calculational significant results in U266 cells can 
only be observed when correlated to Piceatannol, but not to NVP‑BEZ235 (see Additional file 1). Results are expressed as the mean of three panels 
per pattern. Results are from one experiment representative of three. DMSO was used as control. The significance is related to DMSO. +P<1.000, 
*P < 0.1, **P < 0.01, ***P < 0.001. b–e Effects of Syk inhibition in combination with MAP‑Kinase inhibitors are demonstrated. MM cell lines were 
incubated with 5 µM Bay61‑3606 in addition to varying concentrations of U0126 (b), SP600125 (c), PD98059 (d) or SB202190 (e) alone as well as in 
combination. Combined treatment of Bay61‑3606 with U0126 (a potent, selective inhibitor of MAP2K), SP600125 (a selective inhibitor of JNK), or 
PD98059 (an inhibitor of MAP2K/MEK) and SB203580 (a selective inhibitor of p38 MAPK) results in significant synergistic or additive effects. Results 
are expressed as the mean of three panels per pattern. Results are from one experiment representative of three. DMSO was used for negative con‑
trol. The significance is related to DMSO. +P<1.000, *P < 0.1, **P < 0.01, ***P < 0.001.
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To avoid co-elution of the antibody we cross linked 
the primary antibody to Dynabeads®. DSS was eluted in 
DMSO and a working solution consisting of 20× Cou-
pling Buffer (2.5  µl), 2.5  mM DSS and ultrapure water 
(38.5  µl) was established. The Dynabeads®–antibody 
complex was resuspended in 50 µl working solution and 
incubated for 30–60 min in this solution.
Subsequent the Beads were resuspended with the 
whole cell lysates (100–500 µg protein). The Dynabeads®-
antibody–antigen-complex was then incubated for 1  h, 
followed by a couple of steps of washing (3 × 200 µl Wash 
Buffer, 1× 100 µl Wash Buffer), magnetic field exposition 
and resuspending in 20 µl Elution buffer. Afterwards the 
pure precipitate was eluted from the beads of the super-
natant and then analyzed by western blotting (explana-
tion see PAGE and Western Blotting). The blots were 
probed with an antibody against p-syk (purchased from 
Santa Cruz Biotechnology, Inc., Santa Cruz, USA).
Measurement of apoptosis
Apoptosis was measured by the method of Nicoletti [33]. 
1 × 105 cells were incubated in a hypotonic buffer con-
taining 1% sodium citrate, 0.1% Triton X-100, 50  µg of 
propidium iodide per ml and subsequently measured by 
flow cytometry on a Cytomics FC 500 (Beckmann Coul-
ter, Krefeld, Germany) using CXPAnalysis software. The 
hypodiploid cells to the left of the 2N peak were consid-
ered as apoptotic.
Fluorimetric assay of caspase‑3 activity
Caspase activity was determined from cytosolic extracts, 
by the cleavage of the fluorogenic caspase substrate 
N-acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin 
(DEVD-AMC, Bachem, Heidelberg, Germany). In brief, 
for fluorimetric assay of caspase activity, cytosolic cell 
extracts were prepared by lysing cells in a buffer containing 
0.5% NP-40, 20 mM HEPES pH 7.4, 84 mM KCl, 10 mM 
MgCl2, 0.2 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 5 µg/
ml aprotinin, 1  µg/ml leupeptin, 1  µg/ml pepstatin and 
1  mM PMSF. Cell lysates were incubated with 50  mM 
DEVD-AMC in 200 µl buffer containing 37.5 mM HEPES 
pH 7.3, 75  mM NaCl, 7.5% sucrose, 0,075% CHAPS and 
10  mM DTT. The release of aminomethylcoumarin was 
determined by fluorometry using an excitation length of 
360 nm and an emission wave-length of 460 nm.
Phenotyping of MM cells
Cells were treated as mentioned above. After incubation 
staining for fluorescence-activating cell sorting (FACS) 
followed. 5  ×  105 cells/tube were incubated with 10  µl 
anti-CD49d PE (purchased from BD Biosciences Europe, 
Erembodegem, Belgium), CD102 PE (purchased from BD 
Biosciences Europe, Erembodegem, Belgium) or CXCR4 
PE (purchased from Beckman Coulter GmbH, Krefeld, 
Germany) and 10 µl anti-mouse IgG1, κ PE for 30 min at 
18–22°C in the dark. When examined the next day, cells 
were fixed in 250 µl FACS-Buffer and 250 µl 2% formal-
dehyde and then analyzed by flow cytometry.
Proliferation assay
Multiple myeloma cells were seeded into 96-well micro-
titer plates (Greiner Bio-One GmbH, Frickenhausen, 
Germany) at 106, 105 or 104 cells/well and incubated for 
24 h at 37°C, 5% CO2. The assay was performed in four-
fold replicates. Cells were pulsed with 3H-thymidine 
(Hartmann Analytic, Braunschweig, Germany) and incu-
bated for another 16 h at 37°C, 5% CO2. Cells were har-
vested then using a Filter Mate Harvester (Perkin Elmer, 
Waltham, USA) and uptake of 3H-thymidine was meas-
ured by a Microbeta TriLux (Perkin Elmer).
Migration assay
Cells were seeded into transwell chambers (8 µm, BD) in 
24-well plates (BD) and migration was induced through 
SDF-1α (Biovision, Mountain View, CA, USA).
After 3  h migrated multiple myeloma cells were ana-
lyzed by counting gated cells for a time interval of 60 s on 
a Cytomics FC 500 (Beckmann Coulter).
TACS®‑MTT cell proliferation assay
Measurement of cell viability and proliferation were 
performed with TACS®-MTT assay to quantify the cell 
population‘s response to Syk inhibitors. The yellow tetra-
zolium salt 3-4,5-dimethylthiazol-2yl]-2,5-diphenyl-
tetrazolium bromide (MTT) is reduced by metabolic 
active cells and can then be quantitated by spectroscopic 
means. Measurement of proliferation and cell viability 
can be determined over the metabolic events that lead to 
apoptosis or necrosis.
Cells were cultured and treated with Syk Inhibitors as 
mentioned above and then plated in the wells. After add-
ing the MTT agent, cells were incubated in the incubator 
until a purple dye was visible. In the next step Detergent 
Reagent was added and then the flat-bottomed 96-well 
plates were read after 2 h with the microplate reader at 
570  nm. The average value was determined from tripli-
cate reading.
Syk inhibitors
Piceatannol (Sigma-Aldrich Chemie GmbH, Munich, 
Germany), a plant secondary product (3,4,3,5-tetrahy-
droxy-trans-stilbene), was identified as a tyrosine kinase 
inhibitor in thymocytes that also displays some activity 
against Lyn and STATs. The used concentrations were 
adjusted to reported working concentrations in literature. 
BAY61-3606 (Sigma-Aldrich Chemie GmbH, Munich, 
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Germany), (orally available 2-(7-(3,4-dimethoxyphenyl)-
imidazol(1,2-c)pyrimidin-5-ylamino)nicotinamide dihy-
drochloride), is a specific Syk inhibitor that acts as an 
ATP competitor blocking its catalytic activity and was 
shown to inhibit antigen-induced airway inflammation 
in rodents [34]. The used concentrations were adjusted to 
reported working concentrations in literature.
R406 is an adenosine triphosphate competitive, small 
molecule that was developed as a specific Syk inhibitor by 
Rigel Pharmaceuticals (San Francisco, CA, USA) with lower 
activity against FMS-like tyrosine kinase 3 (Flt3), JAK 1/2 
and lymphocyte-specific protein tyrosine kinase (Lck) and 
is currently used in clinical trials for rheumatoid arthritis, 
idiopathic thrombocytopenic purpura (ITP), B-CLL and 
DLBCL. The used concentrations of this compound in our 
experiments represent serum levels obtained in treated 
patients. In volunteers and patients, plasma levels after a sin-
gle dose of R406 between 1 and 5 µg/ml were reported [35].
Statistics
Variance analysis was performed using SPSS 17.0 of SPSS 
Inc. Evaluation of synergistic effects was performed using 
SAS 9.2 from SAS Institute Inc.
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